Mark Berman

Cell Surgical Network (CSN) is a global clinical research organization and medical network focused on the investigation and deployment of autologous adipose-derived stromal vascular fraction (SVF), which contains adult stem cells. Founded by Dr. Mark Berman and Dr. Elliot Lander, the company provides standardized protocols and proprietary technology, such as the CSN Time Machine, to affiliated physicians for the point-of-care treatment of various degenerative, inflammatory, and autoimmune conditions. CSN operates a large network of clinics across the United States and internationally, maintaining a centralized patient registry to track safety and efficacy data for over 15,000 patients. The company has been a prominent figure in high-profile legal challenges regarding the FDA's authority to regulate autologous cell procedures as drugs, advocating for the 'same surgical procedure' exception. Its research pipeline includes investigational studies for indications such as interstitial cystitis, osteoarthritis, and neurodegenerative diseases.